Anticancer Activity of the Amide-Imidazole Compound on Cancer Cell Lines: An In-Vitro Study
BC05-BC08
Correspondence
Preeti Sharma,
Professor, Department of Biochemistry, Santosh Medical College and Hospital, Ghaziabad, Uttar Pradesh, India.
E-mail: pramit2510@gmail.com
Introduction: The leading cause of morbidity and mortality in the world is cancer. Promising anticancer compounds include small heterocyclic chemicals. In many malignancies, cancer cells’ resistance to therapy leads the recurrence and mortality after treatment. Drug resistance that develops during therapy encourages researchers to create compounds that are more useful and less harmful. Derivatives of amido-imidazole conjugates induce apoptosis in breast cancer cell line.
Aim: To investigate the effect of anticancer activity of amide-imidazole on various signalling and apoptotic protein in cancer cell lines.
Materials and Methods: This in-vitro study was designed in the Department of Biochemistry, Santosh Medical College, Ghaziabad, Uttar Pradesh, and AIIMS Patna from February 2021 to January 2022. The normal as well as cancer cell lines were cultured and grown in the medium, and the antiproliferative activity of compounds was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, while various signalling proteins that regulate the proliferation and migration of cancer cell were assessed using the western blotting method. Statistical analysis of antiproliferative activity was estimated using graphical methods.
Results: The results showed that the amide-imidazole compound had variable antiproliferative potency in a variety of cancer cell lines. When HT-29, MDA-MB 231 and MCF-7 cancer cell lines were treated with the amide-imidazole compound at different concentrations (5, 10, 15, and 20 μM). Cell proliferation was inhibited, which is measured by MTT {3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide} assays. The growth in different cancer cells is HT-29 (94.16, 85.19, 77.54, and 77.86), Malondialdehyde (MDA)-MB 231 (100, 91.10, 86.82, and 79.96), and MCF-7 (74.01, 65.26, 60.42, and 36.99) at different concentrations, respectively. The western blot results of the Michigan Cancer Foundation-7 (MCF-7) cancer cell line showed a decrease in the concentration of various signalling pathways such as AKT, Extracellular signal-regulated Kinase (ERK), and Signal Transducer and Activator of Transcription-3 (STAT 3) and an increase in the cleavage of Poly (ADP-ribose) Polymerase (PARP) and Caspase-8, while also decreasing the antiapoptotic protein B-cell Leukaemia (BCL)-2.
Conclusion: In present study, amide-imidazole derivatives triggered the apoptosis and lowered the antiapoptotic cell protein in breast cancer cell lines (MCF-7). Hence, breast cancer, can be treated with amide-imidazole derivatives.